Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus

Pharmacogenomics

Volumn 17, Issue 8, 2016, Pages 867-881

  Jamaluddin, Jazlina Liza ^a   Huri, Hasniza Zaman ^a,b   Vethakkan, Shireene Ratna ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

dipeptidyl peptidase 4 inhibitors; DPP4; HbA1c; KCNJ11; Type 2 diabetes mellitus; WFS1

Indexed keywords

HEMOGLOBIN A1C; LINAGLIPTIN; SITAGLIPTIN; TRIACYLGLYCEROL; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DPP4 GENE; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KCNJ11 GENE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WFS1 GENE; ADOLESCENT; BLOOD; DIABETES MELLITUS, TYPE 2; DIASTOLE; GENETICS; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIASTOLE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; POTASSIUM CHANNELS, INWARDLY RECTIFYING; TRIGLYCERIDES;

EID: 84976483123     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2016-0010     Document Type: Article

References (85)

1. IDF. Diabetes Atlas (6th Edition). International Diabetes Federation, 34 (2013). www.idf.org/
2. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 38(Suppl. 1), S1-S93 (2015).
3. Dicker D. DPP-4 inhibitors. Impact on glycemic control and cardiovascular risk factors. Diabetes Care 34(Suppl. 2), S276-S278 (2011).
4. Jazlina LJ, Hasniza ZH, Shireene V, Norlaila M. Pancreatic gene variants potentially associated with DPP-IV inhibitors treatment response in Type 2 diabetes. Pharmacogenomics 15(2), 235-249 (2014).
5. Seino T, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormone: similarites and differences. J. Diabeters Invest. 1, 9-23 (2010).
6. Gautier JF, Fetita S, Sogngwi E, Martin CS. Biological actions of the incretins GIP and GLP-1 adnd therapeutic perspectives in patients with Type 2 diabetes. Diabetes Metab. 31(3 Pt 1), 233-242 (2005).
7. Drucker DJ. The biology of incretin hormones. Cell Metab. 33, 153-165 (2006).
8. Nauck MA, Baller B, Meier JJ. Gastric inhibitor polypeptid and glucagon-like peptide-1 in the pathogenesis of Type 2 diabetes. Diabetes 53(Suppl. 3), S190-S196 (2004).
9. Mussig K, Staiger H, Machicao F, Haring HU, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 53, 2289-2297 (2010).
10. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidy peptidase-4 inhibitors in Type 2 diabetes. Lancet 368, 1696-1705 (2006).
11. Lacy CF. In: Drug Information Handbook (18th Edition). Armstrong LL, Goldman MP, Lance LL (Eds). Lexi-Comp Inc., OH, USA, 1375-1376 (2009).
12. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am. J. Physiol. Heart Circ. Physiol. 298, H1454-H1465 (2010).
13. National Center for Biotechnology Information (NCBI). www.ncbi.nlm.nih.gov
14. Robinson JW, Gorell MD, Yu DM. Trends in protein research. In: Diverse Functions in a Conserved Structure: The Dipeptidyl peptidase IV Gene Family. Robinson JW (Ed.). Nova Science Publishers, NY, USA 1-79 (2005).
15. Online Mendelian Inheritance in Man. www.ncbi.nlm.nih.gov/omim
16. Barnett A. DPP-4 inhibitors and their potential role in the management of Type 2 diabetes. Int. J. Clin. Pract. 60(11), 1454-1470 (2006).
17. Duez H, Cariou B, Staels B. DPP-4 inhibitors in the treatment of Type 2 diabetes. Biochem. Pharmacol. 83, 823-832 (2012).
18. Fonseca SG, Fukuma M, Lipson KL et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic cells. J. Biol. Chem. 280, 39609-39615 (2005).
19. Ishihara H, Takeda S, Tamura A et al. Disruption of the WFS1 gene in mice causes progressive cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum. Mol. Genet. 13, 1159-1170 (2004).
20. Miki T, Seino S. Roles of KATP channels as metabolic sensors in acute metabolic changes. J. Mol. Cell Cardiol. 38, 917-925 (2005).
21. Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of variants in genes encoding the pancreatic cell KATP channel subunit Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with Type 2 diabetes. Diabetes 52, 568-572 (2003).
22. Kaneko K, Ueki K, Takahashi N et al. Class IA phosphatidylinositol 3-kinase in pancreatic ? cells controls insulin secretionby multiple mechanisms. Cell Metab. 12, 619-632 (2010).
23. Masana MI & Dubocovich ML. Melatonin receptor signaling: finding the path thrugh the dark. Sci STKE. Volume(107), pe39 (2001).
24. WMA. Declaration of Helsinki. Ethical principles for medical research involving human subjects. 59th WMA General Assembly, Seoul 2008. www.wma.net/en
25. Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am. J. Epidemiol. 155(5), 478-484 (2002).
26. Januvia. Product monograph. Merck Canada Inc. www.merck.com
27. Novartis. Galvus product monograph (2012). www.novartis.com.au
28. Tradjenta. Medication guide and full prescribing information. Boehringer-Ingelheim. http://docs.boehringer-ingelheim.com
29. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 35(6), 1364-1379 (2012).
30. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32, 193-203 (2009).
31. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. 10(5), 348-354 (2008).
32. Ohtsuki T, Tsuda H, Morimoto C. Good or evil: CD26 and HIV infection. J. Dermatol. Sci. 22(3), 152-160 (2000).
33. Hübel K, Hegener K, Schnell R et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann. Hematol. 78(2), 73-77 (1999).
34. National Census 2010. Malaysia Institute of Statistics (2010). www.instatmy.org.my
35. Nordborg M. On the probability of Neanderthal ancestry. Am. J. Hum. Genet. 63, 1237-1240 (1998).
36. Bamshad M, Wooding SP. Signature of natural selection in the human genome. Nat. Rev. Genet. 4, 99-111 (2003).
37. National Human Genome Research Institute (NHGRI). The use of racial, ethnic, and ancestral categories in human genetics research. Am. J. Hum. Genet. 77, 519-532 (2005).
38. Department of Pathology. University of Malaya Medical Centre. www.ummc.edu.my
39. Insulin (IRI) assay, ADVIA Centaur, SIEMENS, USA. labmed.ucsf.edu
40. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis modelassessment: insulin resistance and cell function from fasting plasma glucoseand insulin concentrations in man.. Diabetologia. 28, 412-419 (1985).
41. Human sCD26 Platinum ELISA, Bender MedSystems GmbH, Vienna, Austria. www.ebioscience.com
42. The International HapMap Consortium. A haplotype map of the human genome. Nature 437(7063), 1299-1320 (2005).
43. Röhrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front. Immunol. 6, 386 (2015).
44. National Human Genome Research Institute (NHGRI). Sample repository for human genetic research. https://catalog.coriell.org
45. Schosser A, Gaysian D, Cohen-Woods S et al. A follow-up case-control association study of tractable (druggable) genes in recurrent major depression. Am. J. Med. Genet. Part. B 156, 640-650 (2011).
46. Cheng S, Wu Y, Wu W, Zhang D. Association of rs734312 and rs10010131 polymorphisms in WFS1 gene with Type 2 diabetes mellitus: a meta-analysis. Endocr. J. 60(4), 441-447 (2013).
47. Fawcett KA, Wheeler E, Morris AP et al. Detailed investigation of the role of common and low-frequency WFS1 variants in Type 2 diabetes risk. Diabetes 59(3), 741-746 (2010).
48. Haghvirdizadeh P, Mohamed Z, Abdullah NA, Haghvirdizadeh P, Haerian MS, Haerian BS. KCNJ11: genetic polymorphisms and risk of diabetes mellitus. J. Diabetes Res. Article ID 908152 (2015). http://dx.doi.org/10.1155/2015/908152
49. Applied Biosystems. TaqMan SNP Genotyping Assays. https://www3.appliedbiosystems.com
50. Center for Inherited Disease Research (CIDR). www.cidr.jhmi.edu/services/sample.html
51. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 15 January 2005.
52. Lunetta KL. Genetic assocaition studies. Circulation. 118, 96-101 (2008).
53. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47, 1643-1649 (1998).
54. Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW. Framingham Heart Study. The significant effect of diabetes duration on coronary heart disease mortality. Diabetes Care 27, 704-708 (2004).
55. Wallach J. Interpretation of Diagnostic Tests (6th Ed.). Little, Brown, NY, USA (1996).
56. Harris EH. Elevated liver function tests in Type 2 diabetes. Clin. Diabetes 23(3), 115-119 (2005).
57. Tripathy D, Carlsson M, Almgren P et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 49, 975-980 (2000).
58. Esteghamati A, Ashraf H, Khalilzadeh O et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metablic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr. Metab. 7, 26 (2010).
59. Kim YG, Hahn S, Oh TJ et al. Differences in the glucoselowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 56(9), 696-708 (2013).
60. Monami M, Cremasco F, Lamanna C et al. Predictors of response to dipeptidy peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab. Res. Rev. 27(4), 362-372 (2011).
61. Esposito K, Chiodini P, Maiorino MI et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in Type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ 5, e005892 (2015).
62. Tanaka M, Sekioka R, Nishimura T et al. Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with Type 2 diabete mellitus. Diabetol. Int. 6, 197-205 (2015).
63. Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type 2 diabetes. Diabetologia 49(9), 2049-2057 (2006).
64. Lamers D, Famulla S, Wronkowitz N et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60(7), 1917-1925 (2011).
65. Sell H, Bluher M, Kloting N et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 36(12), 4083-4090 (2013).
66. Rosmaninho-Salgado J, Marques AP, Estrada M et al. Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-gamma expression. Peptides 37(1), 49-54 (2012).
67. Turcot V, Bouchard L, Faucher G et al. DPP4 gene DNA methylation in the omentum is associated with its gene expression and plasma lipid profile in severe obesity. Obesity (Silver Spring) 19(2), 388-95 (2011).
68. Shirakawa J, Masaki T, Mitsutomi K et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60(4), 1246-1257 (2011).
69. Shimasaki T, Masaki T, Mitsutomi K et al. The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with dietinduced obesity. PLoS ONE 8(5), e63626 (2013).
70. Fukuda-Tsuru S, Kakimoto T, Utsumi H, Kiuchi S, Ishii S. The novel dipeptidyl peptidase-4 inhibitor tenegliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur. J. Pharmacol. 723, 207-215 (2014).
71. Sufiun A, Rafiq K, Fujisawa Y et al. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hyper. Res. 38, 237-243 (2015).
72. Mason RP, Jacob R, Kubant R, Ciszewski A, Corbalan JJ, Malinski T. Effects of dipeptidyl peptidase-4 inhibition on endothelial nitric oxide release, blood pressure and SICAM-1 levels in hypertensive rats. J. Am. Coll. Cardiol. 59(13s1), E1543 (2012).
73. Mistry GC, Maes AL, Lasseter KC et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J. Clin. Pharmacol. 48, 592-598 (2008).
74. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase IV inhibition on arterial blood pressure. Clin. Exp. Pharmacol. Physiol. 35(1), 29-34 (2008).
75. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 56, 728-733 (2010).
76. Pacheco BP, Crajoinas RO, Couto GK et al. Dipeptidyl peptidase IV inhibition attenuates blood pressue rising in young spontaneous hypertensive rats. J. Hypertens. 29, 520-528 (2011).
77. Hart LM, Fritsche A, Nijpels G et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 62, 3275-3281 (2013).
78. Eizirik DL, Sammeth M, Bouckenooghe T et al. The human pancreatic islet transcriptome: expression of Candidae genes for Type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet. 8, e1002552 (2012).
79. Zimdahl H, Ittrich C, Graefe-Mody U et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidypeptidase-4 inhibitor linagliptin. Diabetologia. 57, 1869-1875 (2014).
80. Javorsky M, Klimcakova L, Schroner Z et al. KCN11 gene E23K variant and therapeutic response to sulphonylureas. Eur. J. Intern. Med.. 23(3), 245-249 (2012).
81. He YY, Zhang R, Shao X-Y et al. Association of KCNJ11 and ABCC8 genetic polymorphisms wth response to repaglinide in Chinese diabetic patients. Acta Pharmacologica Sinica28(3), 983-989 (2008).
82. Sesti G, Laratta E, Cardellini M et al. The E23K variant of KCNJ11 encoding the pancreatic cell adenosine 5-triphosphate-sensitivepotassium channel subunit Kir6.2 is associated with an increased risk ofsecondary failure to sulphonylurea in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91(6), 2334-2339 (2006).
83. Sakamoto Y, Inoue H, Keshavarz P et al. SNPs in the KCNJ11-ABCC8 gene locus are associated with Type 2 diabetes and blood pressure levels in the Japanese population. J. Hum. Genet. 52, 781-793 (2007).
84. Koo BK, Cho YM, Park BL et al. Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with Type 2 diabetes and hypertension in the Korean population. Diabetic Med. 24(2), 178-186 (2007).
85. Liu Z, Zhang Y-W, Feng Q-P et al. Association analysis of 30 Type 2 diabetes candidate genes in Chinese Han population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28(2), 124-128 (2006).